Abstract: The present invention is directed to compounds represented by the formula (1): B-D-Z??(1) [wherein B represent the following formula (B-1), (B-2) or (B-3); A represents an optionally substituted imidazole or pyrazole group; E represents the following formula (1a): X represents an oxygen atom, the formula: SOu, or the formula: N—R9; Y represents a carbon atom or a nitrogen atom; D represents an oxygen atom, a sulfur atom or the formula (1a); Z represents (a chroman-2-yl group, a chroman-4-yl group, a 2,3-dihydrobenzofuran-2-yl group, a 2,3-dihydrobenzofuran-3-yl group, etc.) which is substituted with NHR10 or OR11)] or pharmaceutically acceptable salts thereof, and to antioxidants, therapeutic agents for kidney diseases or cerebrovascular disorder, and retinal oxidative damage inhibitors, which include the compounds as the active ingredient.

Abstract: The present invention relates to a compound represented by formula (1): (wherein, R1, R2, R3 and R4 respectively and independently represent a hydrogen atom or a C1-6 alkyl group, and n represents an integer of 1 or 2) and a production process thereof, as well as an antioxidant that contains the compound as its active ingredient, and a kidney disease treatment agent, cerebrovascular disorder treatment agent, retina oxidative disorder inhibitor and lipoxygenase inhibitor that contain the antioxidant.

Abstract: The present invention relates to a compound represented by formula (1): (wherein R represents a hydrogen atom or a C1-6 alkyl group which may be substituted, A represents an imidazolyl group or a pyrazolyl group, B represents a group represented by the following formula: (wherein R5 and R6 each independently represents a hydrogen atom, a cyano group, a hydroxyl group, a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, or the like, k represents 0 or an integer of 1 to 15, and R5 and R6 may be identical or different from each other, when k is 2 or more), and Z represents a substituted chroman-2-yl group, a substituted 2,3-dihydrobenzofuran-2-yl, a substituted thiochroman-2-yl group, a substituted 2,3-dihydrobenzothiophene-2-yl group, or a substituted 1,3-benzoxathiol-2-yl group).

Abstract: Thieno[2,3-d]pyrimidine compounds of general formula (1) useful as drugs having a cGMP-specific phosphodiesterase inhibiting effect and the preparation thereof wherein Q is formula: (CH2)n—N(r1)—C(r2) (r3), CH═CH—CH═CH, or (CH2)m which is bonded to a and b; R1 is hydrogen or C1-C6 alkyl; R2 is C3-C8 cycloalkyl optionally substituted with G1, phenyl optionally substituted with G2, or a saturated or unsaturated heterocyclic group having 1 to 4 heteroatoms selected from N, O and S and being optionally substituted with G3; and R3 is a saturated or unsaturated heretocyclic group having 1 to 4 heteroatoms selected from N, O and S and being optionally substituted with G3 or (CH2)kC(═O)R4 or CH═CHC(O)R4.

Abstract: The present invention provides a method and a tower for removing residual monomers in the manufacture of vinyl chloride resins (PVC). When residual monomers are removed from a PVC slurry after the slurry has undergone a polymerization due to contact with steam, the bubbles generated in the slurry are controlled to maintain stable fluid conditions. Residual monomers are effectively removed, and inclusion of foreign matter is inhibited. The tower has two or more levels and is divided into upper and lower sections. The inner diameter of the upper section is greater than that of the lower section. Each section is provided with at least one perforated tray. In addition, at least one hot water-ejecting device is provided in the tower.

Abstract: Phenylazole compounds represented by general formula (1) or pharmaceutically acceptable salts thereof and drugs for hyperlipemia which contain these compounds as the active ingredient, wherein A represents imidazolyl, pyrazolyl, etc.; B represents (1a) or (1b) (wherein R2 and R3 represent each hydrogen, C1-6 alkyl, etc; and k is 0 or an integer of 1 to 15); Y represents O, S, a bond, etc.; and Z represents an optionally substituted and saturated or unsaturated heterocycle containing 1 to 4 N, O or S atoms. Among all, compounds wherein Z is substituted chroman-2-yl, 2,3-dihydrobenzofuran-2-yl, etc. have an effect of inhibiting the formation of lipid peroxides too.

Abstract: The present invention is to provide novel imidazole derivatives effectual as an antihyperlipemic agent and therapeutic and preventive drugs for arteriosclerosis, and to provide methods for manufacturing the said derivatives.More particularly, the present invention is directed to the compounds represented by the following general formula [I]; ##STR1## wherein R.sup.1 is hydrogen or lower alkyl, n is 0 or 1, X is N-r.sup.1 wherein r.sup.1 is hydrogen or lower alkyl, O, S, SO, SO.sub.2, CH.sub.2, CH(CH.sub.3), CONH or C(r.sup.2).dbd.NO wherein r.sup.2 is hydrogen or lower alkyl, m is 0 or an integer of from 1 to 12, and A is methyl or a group represented by the following general formula; ##STR2## wherein Y is N-r.sup.3 wherein r.sup.3 is hydrogen or lower alkyl, N(r.sup.4)SO.sub.2 wherein r.sup.4 is hydrogen or lower alkyl, O, S, SO, SO.sub.2, CH.sub.2, CH(CH.sub.3), CONH or C(r.sup.5).dbd.NO wherein r.sup.5 is hydrogen or lower alkyl, R.sup.2 is a halogen, a lower alkyl, a lower alkoxy, a cycloalkyl or COOr.

Abstract: The present invention is directed to (R)-(-)-4,5-dihydro-5-methyl-6-?4-?(2-propyl-3-oxo-1-cyclohexenyl)amino!ph enyl!-3(2H)-pyridazinone, the crystalline form thereof and a method for manufacturing the said compound and the said crystalline form.The compound of the present invention has excellent inhibitory effect on platelet aggregation while giving less side effect, and therefore, it is useful to utilize the compound as an antithrombotic drug. In addition, the compound of the present invention has bronchodialatic effect as well, and it is therefore useful to utilize the compound for chemotherapy of chronic obstructive lung disease, such as asthma and bronchitis.Moreover, the compound of the present invention is useful for chemotherapy of the diseases relating to the concentration of cAMP in cells, such as hypertension, ulcer, diabetes mellitus and cancer.Again, crystalline form of the said compound is the most suitable form in order to supply stable and homogeneous bulk thereof.

Abstract: A method for removing residual vinyl chloride monomers from an aqueous slurry is disclosed. The method preferably utilizes a tower having a plurality of vertically spaced plates, which define a plurality of chambers, each chamber defined between adjacent plates. The tower features a plate in one of the chambers having a diameter of 1.05 to 5 times larger than the diameter of the plates in chambers above and below the chamber having the large plate. The method is based upon introducing the slurry to a particular location in the tower depending upon the porosity of the polyvinyl chloride in the slurry.

Abstract: A printing plate consisting of a base portion, a mount portion and a relief portion made of a liquid resin which is sensitive to and curable by irradiated, activating rays, the plate being prepared by use of a masking sheet formed with a transmitting pattern having a contour corresponding to and slightly larger than the pattern of a negative film, a semi-transmitting pattern positioned outside the transmitting pattern and having a large contour for transmitting irradiated activating rays upon attenuation, and a blocking surface positioned outside the semi-transmitting pattern and having an effect to block the activating rays to an extent not to cure the liquid resin layer.

Abstract: An improvement in a process for preparing a macrocyclic ketone having from 12 to 18 carbon atoms which comprises intramolecular cyclization of a lower alcohol diester of a straight chain alkanedicarboxylic acid having from 12 to 18 carbon atoms by acyloin condensation and reduction of the resulting 2-hydroxycycloalkanone is disclosed. The improvement comprises conducting the acyloin condensation in a water-immiscible organic solvent having a boiling point of not lower than 40.degree.C., subjecting the resulting organic solvent solution containing the 2-hydroxycycloalkanone to reduction, and conducting the reduction in the copresence of said organic solvent and water. The macrocyclic ketone can be prepared at high efficiency.

Abstract: A process comprising the steps of preparing from a positive original transparent film pieces bearing the image of the original in a positive form for color separation, fixedly laying out each of the film pieces on a transparent film for each of the separated colors, and making a printing plate for each color with use of the transparent film having the film piece thereon.

Abstract: A printing plate consisting of a base portion, a mount portion and a relief portion made of a liquid resin which is sensitive to and curable by irradiated activating rays, the plate being prepared by use of a masking sheet formed with a transmitting pattern having a contour corresponding to and slightly larger than the pattern of a negative film, a semi-transmitting pattern positioned outside the transmitting pattern and having a large contour for transmitting irradiated activating rays upon attenuation, and a blocking surface positioned outside the semi-transmitting pattern and having an effect to block the activating rays to an extent not to cure the liquid resin layer.

Abstract: A printing plate consisting of a base portion, a mount portion and a relief portion made of a liquid resin which is sensitive to and curable by irradiated activating rays, the plate being prepared by use of a masking sheet formed with a transmitting pattern having a contour corresponding to and slightly larger than the pattern of a negative film, a semi-transmitting pattern positioned outside the transmitting pattern and having a large contour for transmitting irradiated activating rays upon attenuation, and a blocking surface positioned outside the semi-transmitting pattern and having an effect to block the activating rays to an extent not to cure the liquid resin layer.

Abstract: In a reactor for cracking heavy hydrocarbon oil through a fluidized bed of the particles of natural ores, coke-like materials are deposited on a top of the reactor or pipe inside surfaces of a transfer line from the reactor to a scrubber. To effectively scour out the deposited coke-like materials, particles of natural ores having a mean diameter of a few hundred .mu.m is made to be contained in an effluent gas from the top of reactor, passing through the transfer line at a concentration of 1 to 40 g/m.sup.3. The particles of natural ores have a good effect of scouring out the deposited coke-like materials and can keep the transfer line efficiently clean even with a small amount of the particles of natural ores, decreasing a pressure drop in the transfer line.

Abstract: A method for the oxidation of hydrocarbons to monocarboxylic acids and then to dicarboxylic acids by the aerobic cultivation or resting cell reaction of the organism Debaryomyces vanriji (BR-308) ATCC 20588.

Abstract: In a reactor for cracking heavy hydrocarbon oil through a fluidized bed of particles of natural ores, coke-like materials are deposited on a top of the reactor or pipe inside surfaces of a transfer line from the reactor to a scrubber. To effectively scour out the deposited coke-like materials, particles of natural ores having a mean diameter of a few hundred .mu.m is made to be contained in an effluent gas from the top of reactor, passing through the transfer line at a concentration of 1 to 40 g/m.sup.3. The particles of natural ores have a good effect of scouring out the deposited coke-like materials and can keep the transfer line efficiently clean even with a small amount of the particles of natural ores, decreasing a pressure drop in the transfer line.

Abstract: A method for the oxidation of hydrocarbons to monocarboxylic acids and thence to dicarboxylic acids by the aerobic resting cell reaction of the organism Debaryomyces phaffii ATCC 20499.